Hims & Hers Health, Inc. HIMS

Healthcare SIC 8011 - Services-Offices & Clinics of Doctors of Medicine NYSE

Launched in 2017, Hims & Hers Health, Inc. (and together with its subsidiaries, "Hims & Hers", the "Company", "we", "us" or "our") has built a consumer-first platform transforming the way customers fulfill their health and wellness needs. We believe that the Company has the technical infrastructure, distributed provider network, and access to clinical capabilities to lead the migration of routine office visits to a personalized, digital, accessible format. The Hims & Hers platforms (collectively, our "platform") include access to a highly-qualified and technologically-innovative provider network, an electronic medical record system designed to support providers and customers, digital prescriptions, cloud pharmacy fulfillment, and personalization capabilities. Our digital platform enables access to treatments for a broad range of chronic conditions, including those related to sexual health, hair loss, hormone health, weight loss, dermatology, and mental health, as well as services such as comprehensive laboratory testing. Hims & Hers connects patients to licensed healthcare professionals who can prescribe medications when appropriate, including through personalized treatment plans, with prescriptions fulfilled online through licensed pharmacies. In addition, we also offer access to a range of non-prescription health and wellness products. Through the Hims & Hers mobile applications, consumers can access a range of educational programs, wellness content, community support, and other services that promote lifelong health and wellness. Since our founding, we have facilitated over fifty million telehealth consultations, enabling greater access to high-quality, convenient, affordable, personalized care for people in the United States, Canada, the United Kingdom, and the European Union (in Germany, the Republic of Ireland, France, and Spain).

Last close 27.71 2026-09-04
Market cap $6.42B estimated share count
52-week range 13.74 - 65.30

Valuation FY2025 figures against the last close

P/S2.7x
P/E54.3x
P/FCF111.9x
EV/EBITDA40.1x
Dividend yield
Diluted EPS0.51

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Revenue $2.35B$1.48B$872.0M$526.9M$271.9M$148.8M$82.6M
Cost of revenue $614.3M$303.4M$157.1M$118.2M$67.4M$39.3M$38.0M
Gross profit $1.73B$1.17B$714.9M$408.7M$204.5M$109.5M$44.6M
SG&A $272.7M$167.8M$129.9M$98.2M$113.7M$26.0M$55.9M
Total operating expenses $1.63B$1.11B$744.4M$477.4M$319.5M$124.6M$119.0M
Operating income $105.6M$61.9M-$29.5M-$68.7M-$115.0M-$15.1M-$74.4M
Interest expense $0$10.0K$369.0K
Pre-tax income $123.9M$71.7M-$21.6M-$65.7M-$110.8M-$18.0M-$72.0M
Income tax $4.4M$54.3M$2.0M$31.0K$3.1M$127.0K$90.0K
Net income $128.4M$126.0M-$23.5M-$65.7M-$107.7M-$18.1M-$72.1M
EPS, basic 0.570.58-0.11-0.32-0.58-0.51-2.07
EPS, diluted 0.510.53-0.11-0.32-0.58-0.51-2.07
Shares, diluted (wtd. avg.) $258.2M$236.8M$209.3M$204.5M$186.8M$35.4M$34.8M

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Cash and equivalents $228.6M$220.6M$96.7M$47.6M$72.6M$28.4M$22.8M$41.6M
Short-term investments $348.9M$79.7M$124.3M$132.9M$175.5M$72.9M
Receivables $32.1M$6.1M$6.7M$3.9M$4.1M$1.1M
Inventory $80.1M$64.4M$22.5M$21.6M$13.6M$3.5M
Total current assets $767.6M$395.8M$265.1M$216.6M$269.9M$113.1M$1.7M
Property, plant and equipment $3.0M$2.2M$1.7M
Goodwill $278.3M$112.7M$110.9M$110.9M$110.9M$0
Other intangibles $196.1M$43.4M$18.6M$21.8M$25.9M$59.0K
Total assets $2.15B$707.5M$441.2M$366.3M$420.6M$118.7M$204.8M
Accounts payable $143.3M$91.2M$43.1M$32.4M$19.6M$8.1M$18.5K
Total current liabilities $404.4M$221.4M$88.5M$47.9M$79.2M$15.2M$979.4K
Total liabilities $1.61B$230.8M$97.2M$54.6M$86.0M$15.6M$8.2M
Retained earnings -$113.8M-$242.1M-$368.2M-$344.6M-$279.0M-$171.3M$1.1M
Total equity $540.9M$476.7M$344.0M$311.7M$334.6M-$146.9M-$139.8M-$71.4M

Cash flow

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Operating cash flow $300.0M$251.1M$73.5M-$26.5M-$34.4M-$2.5M-$74.9M
Depreciation and amortisation $54.5M$17.1M$9.5M$7.5M$4.1M$1.1M$260.0K
Stock-based compensation $135.2M$92.3M$66.1M$42.8M$67.2M$5.8M$8.0M
Capital expenditure $242.6M$52.8M$26.5M$7.2M
Investing cash flow -$1.02B-$19.0M-$12.1M$34.7M-$156.3M-$39.7M-$39.3M
Financing cash flow $729.6M-$107.8M-$11.5M-$33.1M$235.0M$47.7M$95.3M
Buybacks $90.0M$83.0M$2.0M$0$0$0$0

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001773751-26-000060.

Others in SIC 8011

TickerCompanyMarket capP/ERevenue growth
TDOC Teladoc Health, Inc. $1.14B -1.5%
STLN Starling Oncology, Inc. $604.4M 27.8%
SBC SBC Medical Group Holdings Inc $423.7M 8.2x -15.5%
AIRS Airsculpt Technologies, Inc. $201.5M -15.8%
LFMD LifeMD, Inc. $148.5M 12.3x 25.3%
CCM Concord Medical Services Holdings Ltd 26.6%
BMGL Basel Medical Group Ltd